---
title: "UBS maintains Kodiak Sciences at Buy, raises price target to $150 from $120"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305489896.md"
description: "UBS maintained Kodiak Sciences at Buy and raised its price target to $150 from $120, a 25.0% increase.The price target implies an upside of 38.6% from the Nov 12 close of $108.25.Explore more price target data and ratings for Kodiak Sciences on the , and track all previous and future analyst recommendations in the dedicated News Flow.DisclaimerSelect reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice."
datetime: "2026-11-13T16:44:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305489896.md)
  - [en](https://longbridge.com/en/news/305489896.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305489896.md)
generator: "portal-rs"
---

# UBS maintains Kodiak Sciences at Buy, raises price target to $150 from $120

UBS maintained Kodiak Sciences at Buy and raised its price target to $150 from $120, a 25.0% increase.

The price target implies an upside of 38.6% from the Nov 12 close of $108.25.

Explore more price target data and ratings for Kodiak Sciences on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [KOD.US](https://longbridge.com/en/quote/KOD.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)

## Related News & Research

- [Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01](https://longbridge.com/en/news/305374957.md)
- [Did Phase 3 Eye Drug Results Just Shift Kodiak Sciences (KOD) Investment Narrative?](https://longbridge.com/en/news/305493238.md)
- [KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones](https://longbridge.com/en/news/305683102.md)
- [U.S. RESEARCH ROUNDUP- Aecom, Anthropic, Strategy](https://longbridge.com/en/news/306081132.md)
- [Will Revenue Outlook Cut Change Lululemon Stock's Narrative](https://longbridge.com/en/news/305993397.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**